1. Home
  2. CCCT vs IPSC Comparison

CCCT vs IPSC Comparison

Compare CCCT & IPSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CCCT

Columbus Circle Capital Corp III Class A Ordinary Shares

N/A

Current Price

$9.85

Market Cap

308.6M

Sector

N/A

ML Signal

N/A

Logo Century Therapeutics Inc.

IPSC

Century Therapeutics Inc.

N/A

Current Price

$1.18

Market Cap

248.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CCCT
IPSC
Founded
2025
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
308.6M
248.1M
IPO Year
2026
2021

Fundamental Metrics

Financial Performance
Metric
CCCT
IPSC
Price
$9.85
$1.18
Analyst Decision
Buy
Analyst Count
0
5
Target Price
N/A
★ $4.75
AVG Volume (30 Days)
27.3K
★ 876.8K
Earning Date
N/A
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 91.30
EPS
★ N/A
N/A
Revenue
N/A
★ $109,164,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 1556.76
52 Week Low
$9.80
$0.48
52 Week High
$10.05
$2.97

Technical Indicators

Market Signals
Indicator
CCCT
IPSC
Relative Strength Index (RSI) 55.97 34.74
Support Level $9.80 N/A
Resistance Level $9.88 $2.45
Average True Range (ATR) 0.00 0.19
MACD -0.00 -0.04
Stochastic Oscillator 40.00 2.07

Price Performance

Historical Comparison
CCCT
IPSC

About CCCT Columbus Circle Capital Corp III Class A Ordinary Shares

Columbus Circle Capital Corp III is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

About IPSC Century Therapeutics Inc.

Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.

Share on Social Networks: